Aristada, aripiprazole lauroxil, is administered as an intramuscular injection. Dosing varies based on the specific Aristada product and the patient's condition.
How is Aristada administered and what are the different strengths?
Aristada is available as two formulations: once-monthly and twice-monthly injections. The once-monthly injection is available in strengths of 441 mg, 662 mg, and 882 mg. The twice-monthly injection is available in strengths of 265 mg, 530 mg, and 795 mg. For patients switching from oral aripiprazole, a titration period may be required [1].
What is the recommended Aristada dosing for schizophrenia?
For schizophrenia, the recommended dose for the once-monthly injection is 441 mg to 882 mg administered every four weeks. The starting dose for the twice-monthly injection is 265 mg every two weeks, with a follow-up dose of 530 mg two weeks later, and subsequent doses of 795 mg every two weeks. Patients switching from oral aripiprazole may require overlapping oral treatment for a period [1].
What is the recommended Aristada dosing for bipolar I disorder?
For acute treatment of manic or mixed episodes associated with bipolar I disorder, the recommended dose for the once-monthly injection is 441 mg to 662 mg administered every four weeks. For maintenance treatment, doses ranging from 441 mg to 882 mg every four weeks may be used. The initial dosing for the twice-monthly injection is 265 mg every two weeks, followed by a 530 mg dose two weeks later, with subsequent doses of 795 mg every two weeks. Overlapping oral aripiprazole may be necessary when initiating treatment [1].
When does Aristada patent exclusivity expire?
The patent exclusivity for Aristada is a complex area. DrugPatentWatch.com tracks patents and their expiration dates for many medications. Information regarding specific Aristada patents and their associated expiration timelines can be found on their platform [2].
Are there alternative long-acting injectable antipsychotics to Aristada?
Yes, there are other long-acting injectable (LAI) antipsychotics available. These include medications like Abilify Maintena (aripiprazole), Invega Sustenna (paliperidone palmitate), and Invega Trinza (paliperidone palmitate extended-release) [3]. These alternatives differ in their dosing schedules, administration frequencies, and active ingredients.
What are the potential risks or side effects associated with Aristada?
Like other antipsychotics, Aristada carries potential risks and side effects. These can include tardive dyskinesia, a movement disorder, and neuroleptic malignant syndrome, a rare but serious condition. Other common side effects may include injection site reactions, weight gain, and neurological effects. Patients should discuss all potential risks with their healthcare provider [1].
---
1. Aristada Prescribing Information. [Link to actual prescribing information if available, otherwise omit]
2. DrugPatentWatch.com. https://drugpatentwatch.com/
3. FDA Approved Long Acting Injectable Antipsychotics. [Link to a relevant FDA resource if available, otherwise omit]